Do you recommend neoadjuvant chemotherapy or induction chemo + chemoRT for borderline resectable pancreatic cancer?
How would the new data presented at ASCO GI 2021 from from Alliance A021501 influence your answer?
Answer from: Radiation Oncologist at Academic Institution
The definition of BRPC has expanded to include everything from minimal venous involvement to 180 degree abutment of the SMA. It is important to determine if there is arterial involvement. If there is, the best data show that XRT helps with R0 resections. In our experience at MDACC, ...
Comments
Medical Oncologist at Greenville Health System Cancer Institute BRPC is such a poor prognosis disease that I have ...
Answer from: Radiation Oncologist at Academic Institution
It is true that 54Gy of XRT did not improve OS in locally advanced patients in the LAP-07 trial, but that study is not relevant to the BRPC population with arterial involvement (also T4 but resectable) where the issue is improving margin negative resectability. Margins are +80% of the time wit...
Answer from: Medical Oncologist at Academic Institution
I would add the findings of Hammel et al. published in JAMA recently: patients with stage III locally advanced disease (so T4, unresectable at diagnosis) were randomized to chemo (gemcitibine, since the trial was started before FOLFIRINOX and Abraxane) vs. chemoRT (after an earlier randomization to ...
BRPC is such a poor prognosis disease that I have ...